Advertisement


Laura C. Michaelis, MD: In My Experience Question 4

COVID-19 and Cancer Care

Advertisement

At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?

Recorded April 24, 2020.



Related Videos

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 1

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?

Recorded April 24, 2020.

COVID-19

Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations

Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.

COVID-19

William Dale, MD, PhD, on Best Practices for Special Populations During the COVID-19 Pandemic

William Dale, MD, PhD, of City of Hope National Medical Center, discusses vulnerable populations—older adults and those with psychosocial or mental health concerns—and reviews best practices for treatment decisions, social distancing, and maintaining emotional health. Recorded April 15, 2020.

COVID-19
Global Cancer Care

Rafal Dziadziuszko, MD, PhD, on Helping Ease Oncology Patients’ Fears of Contracting COVID-19

Rafal Dziadziuszko, MD, PhD, of the Medical University of Gdansk, discusses the concerns his patients with cancer have about exposure to COVID-19 when they come to his institution for care and how he manages their fears. Filmed April 24, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 3

Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma?

Recorded April 24, 2020.

Advertisement

Advertisement




Advertisement